More on ESAIY

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:ESAIY)
Delayed: 8.00 -0.05 (0.62%)
Prev. Close $8.05  
Open$8.00 
52 Wk High$ 
52 Wk Low$ 
Day High$8.12 
Day Low$7.88 
P/E N/A  
EPS$ 
Volume41,978 

Friends, Peers and Foes (?): ESALF, EII BIIB (more...)

Sep 18, 2026 11:45 AM LEQEMBI(R) Pen (Subcutaneous Formulation of LEQEMBI(R)) Approved in Japan for the Treatment of Early Alzheimer's Disease
Sep 15, 2026 10:04 AM Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)
Aug 27, 2026 02:58 PM LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
Jul 27, 2026 02:50 PM Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
Jul 17, 2026 07:21 PM EMA accepts Eisai's lemborexant application for insomnia treatment
Jul 17, 2026 07:21 PM Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 15, 2026 02:51 PM LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months
Jul 15, 2026 01:29 PM FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
Jul 15, 2026 01:29 PM FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 01:01 PM Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R))
View All Articles

Entities mentioned with ESAIY

View All Entities